Literature DB >> 27766215

PEGylated Human Serum Albumin: Review of PEGylation, Purification and Characterization Methods.

Parvin Akbarzadehlaleh1, Mona Mirzaei2, Mahdiyeh Mashahdi-Keshtiban2, Karim Shamsasenjan3, Hamidreza Heydari2.   

Abstract

Human serum albumin (HSA) is a non-glycosylated, negatively charged protein (Mw: about 65-kDa) that has one free cystein residue (Cys 34), and 17 disulfide bridges that these bridges have main role in its stability and longer biological life-time (15 to 19 days). As HSA is a multifunctional protein, it can also bind to other molecules and ions in addition to its role in maintaining colloidal osmotic pressure (COP) in various diseases. In critical illnesses changes in the level of albumin between the intravascular and extravascular compartments and the decrease in its serum concentration need to be compensated using exogenous albumin; but as the size of HSA is an important parameter in retention within the circulation, therefore increasing its molecular size and hydrodynamic radius of HSA by covalent attachment of poly ethylene glycol (PEG), that is known as PEGylation, provides HSA as a superior volume expander that not only can prevent the interstitial edema but also can reduce the infusion frequency. This review focuses on various PEGylation methods of HSA (solid phase and liquid phase), and compares various methods to purifiy and characterize the pegylated form.

Entities:  

Keywords:  HSA; Human Serum Albumin; PEGylated albumin; PEGylation

Year:  2016        PMID: 27766215      PMCID: PMC5071794          DOI: 10.15171/apb.2016.043

Source DB:  PubMed          Journal:  Adv Pharm Bull        ISSN: 2228-5881


  25 in total

Review 1.  Effect of pegylation on pharmaceuticals.

Authors:  J Milton Harris; Robert B Chess
Journal:  Nat Rev Drug Discov       Date:  2003-03       Impact factor: 84.694

Review 2.  Therapeutic apheresis: use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange.

Authors:  Bruce C McLeod
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

3.  The effect of PEGylation on the stability of small therapeutic proteins.

Authors:  Thomas Palm; Reza Esfandiary; Rajesh Gandhi
Journal:  Pharm Dev Technol       Date:  2011-01-24       Impact factor: 3.133

4.  PEGylation enhancement of pH stability of uricase via inhibitive tetramer dissociation.

Authors:  Hong Tian; Yuan Guo; Xiangdong Gao; Wenbing Yao
Journal:  J Pharm Pharmacol       Date:  2012-07-30       Impact factor: 3.765

5.  MALDI linear TOF mass spectrometry of PEGylated (glyco)proteins.

Authors:  Birgit K Seyfried; Jürgen Siekmann; Omar Belgacem; Ryan J Wenzel; Peter L Turecek; Günter Allmaier
Journal:  J Mass Spectrom       Date:  2010-06       Impact factor: 1.982

6.  New PEGs for peptide and protein modification, suitable for identification of the PEGylation site.

Authors:  F M Veronese; B Saccà; P Polverino de Laureto; M Sergi; P Caliceti; O Schiavon; P Orsolini
Journal:  Bioconjug Chem       Date:  2001 Jan-Feb       Impact factor: 4.774

7.  Volume resuscitation from hemorrhagic shock with albumin and hexaPEGylated human serum albumin.

Authors:  Pedro Cabrales; Amy G Tsai; K Ananda; Seetharama A Acharya; Marcos Intaglietta
Journal:  Resuscitation       Date:  2008-07-14       Impact factor: 5.262

Review 8.  Chemistry for peptide and protein PEGylation.

Authors:  M J Roberts; M D Bentley; J M Harris
Journal:  Adv Drug Deliv Rev       Date:  2002-06-17       Impact factor: 15.470

9.  A solid-phase adsorption method for PEGylation of human serum albumin and staphylokinase: preparation, purification and biochemical characterization.

Authors:  Xiaoyan Suo; Xiuling Lu; Tao Hu; Guanghui Ma; Zhiguo Su
Journal:  Biotechnol Lett       Date:  2009-04-03       Impact factor: 2.461

10.  Native PAGE eliminates the problem of PEG-SDS interaction in SDS-PAGE and provides an alternative to HPLC in characterization of protein PEGylation.

Authors:  Chunyang Zheng; Chunyang Y Zheng; Guanghui Ma; Zhiguo Su
Journal:  Electrophoresis       Date:  2007-08       Impact factor: 3.535

View more
  5 in total

1.  Development of a novel multi-functional integrated bioconjugate effectively targeting K-Ras mutant pancreatic cancer.

Authors:  Yang-Yang Wang; Liang Li; Xiu-Jun Liu; Qing-Fang Miao; Yi Li; Meng-Ran Zhang; Yong-Su Zhen
Journal:  J Pharm Anal       Date:  2021-07-03

2.  Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy.

Authors:  Haitao Pan; Jiayu Liu; Wentong Deng; Jieyu Xing; Qing Li; Zhong Wang
Journal:  Int J Nanomedicine       Date:  2018-05-29

3.  Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated αIIbβ3 Antagonist, Disintegrin.

Authors:  Yu-Ju Kuo; Yao Tsung Chang; Ching-Hu Chung; Woei-Jer Chuang; Tur-Fu Huang
Journal:  Toxins (Basel)       Date:  2020-06-28       Impact factor: 4.546

4.  Novel site-specific PEGylated L-asparaginase.

Authors:  Giovanna Pastore Meneguetti; João Henrique Picado Madalena Santos; Karin Mariana Torres Obreque; Christiano Marcello Vaz Barbosa; Gisele Monteiro; Sandra Helena Poliselli Farsky; Adriano Marim de Oliveira; Claudia Blanes Angeli; Giuseppe Palmisano; Sónia Patrícia Marques Ventura; Adalberto Pessoa-Junior; Carlota de Oliveira Rangel-Yagui
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

5.  Conformational stability as a quality attribute for the cell therapy raw material human serum albumin.

Authors:  Evelien Wynendaele; Gamaliel Junren Ma; Xiaolong Xu; Nam-Joon Cho; Bart De Spiegeleer
Journal:  RSC Adv       Date:  2021-04-23       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.